Huahao Zhongtian Pharmaceutical-B (02563.HK) announced that it recently signed a market promotion service agreement with Baiyang Pharmaceutical (301015.SZ), a wholly-owned subsidiary of Baiyang Intelligence. According to the market promotion service agreement, the company agrees to grant Baiyang Intelligence exclusive market promotion services for Yutide Long injection (commodity name Yutidi) in mainland China.

In addition, the company, its wholly-owned subsidiary Chengdu Huahao Zhongtian, and Baiyang Intelligence signed a supplementary agreement to the market promotion service agreement. According to the supplementary agreement, all parties agree to authorize Baiyang Intelligence to exclusively and exclusively promote specified products in the designated area in accordance with the market promotion service agreement, and Chengdu Huahao Zhongtian will inherit all rights and obligations of the company under the market promotion service agreement.